ArticleEBioMedicine2021
Production and characterization of a human antisperm monoclonal antibody against CD52g for topical contraception in women.
Article in EBioMedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- Complement protein concentrations and activity in human cervical mucus.bioRxiv : the preprint server for biology · 2026Article
- Sialidases derived frombioRxiv : the preprint server for biology · 2025Article
- Revolutionizing male contraception: Personal lubricants as a novel way to deliver the Human Contraception Antibody.bioRxiv : the preprint server for biology · 2025Article
- PSA inhibitors for contraception: insights from prostate cancer.Trends in pharmacological sciences · 2025Review
- Review
- Vaginally-delivered fast-dissolving antibody tablets (FDAT) for on-demand non-hormonal contraception and multi-purpose protection.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Antibody-dependent complement-mediated sperm cytotoxicity in the endocervix is a dominant contraceptive mechanism of ZB-06 vaginal film.Fertility and sterility · 2025Article
- Non-hormonal Contraception: Current and Emerging Targets.Advances in experimental medicine and biology · 2025Review
- The Molecular Mechanisms of Natural Medicinal Active Ingredients Interfering with Male Fertility.Current pharmaceutical design · 2025Review
- Vaginal irritation testing-prospects of human organotypic vaginal tissue culture models.In vitro cellular & developmental biology. Animal · 2024Review
- Reversible female contraceptives: historical, current, and future perspectives†.Biology of reproduction · 2024Review
- Non-Hormonal Contraception.Journal of clinical medicine · 2023Review
- ZB-06, a vaginal film containing an engineered human contraceptive antibody (HC4-N), demonstrates safety and efficacy in a phase 1 postcoital test and safety study.American journal of obstetrics and gynecology · 2023Article
- A brief history and future prospects of contraception.Science (New York, N.Y.) · 2023Review
- A Brief History and Advancement of Contraceptive Multipurpose Prevention Technology (cMPT) Products.Open access journal of contraception · 2023Review
- Immunology of Pregnancy and Systemic Consequences.Current topics in microbiology and immunology · 2023Article
- Article
- Innovations in monoclonal antibody-based multipurpose prevention technology (MPT) for the prevention of sexually transmitted infections and unintended pregnancy.Frontiers in reproductive health · 2023Review
- Screening of sperm antigen epitopes by phage display technique and its preliminary clinical application.Basic and clinical andrology · 2022Article
- Toxicity Assessment of Resveratrol Liposomes-in-Hydrogel Delivery System by EpiVaginalPharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundApproximately 40% of human pregnancies are unintended, indicating a need for more acceptable effective contraception methods. New antibody production systems make it possible to manufacture reagent-grade human monoclonal antibodies (mAbs) for clinical use. We used the Nicotiana platform to produce a human antisperm mAb and tested its efficacy for on-demand topical contraception.
methodsHeavy and light chain variable region DNA sequences of a human IgM antisperm antibody derived from an infertile woman were inserted with human IgG
findingsHCA was obtained at concentrations ranging from 0.4 to 4 mg/ml and consisted of > 90% IgG monomers. The mAb specifically reacted with a glycan epitope on CD52g, a glycoprotein produced in the male reproductive tract and found in abundance on sperm. HCA potently agglutinated sperm under a variety of relevant physiological conditions at concentrations ≥ 6.25 µg/ml, and mediated complement-dependent sperm immobilization at concentrations ≥ 1 µg/ml. HCA and its immune complexes did not induce inflammation in EpiVaginal™ tissue.
interpretationHCA, an IgG1 mAb with potent sperm agglutination and immobilization activity and a good safety profile, is a promising candidate for female contraception.
fundingThis research was supported by grants R01 HD095630 and P50HD096957 from the National Institutes of Health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.